FAQ

LBM415

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2011
01220042011

Related topics

Related topics

1 relation

Broader (1)

NVP PDF 713

Related mentions per year

Related mentions per year

2003-2018
20002005201020152020
LBM415
NVP PDF 713

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor.
Peptide deformylase (PDF) inhibitors represent a potential new class of antibiotics targeting a large number of bacterial species… (More)
Is this relevant?
2009
2009
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
LBM415 is an antibacterial agent belonging to the peptide deformylase inhibitor class of compounds. It has previously been shown… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
Previous genetic analysis of Haemophilus influenzae revealed two mechanisms associated with decreased susceptibility to the novel… (More)
Is this relevant?
2007
2007
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
LBM415 is a peptide deformylase inhibitor active against gram-positive bacterial species and some gram-negative species. In… (More)
Is this relevant?
2006
2006
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
OBJECTIVES To evaluate the spectrum of activity and potency of LBM415, the first of the peptide deformylase inhibitor (PDFI… (More)
  • table 1
  • table 2
  • table 2
  • table 2
  • table 3
Is this relevant?
2006
2006
Multistep Resistance Selection and Pae Studies on Antipneumococcal Activity of Lbm415 Compared to Other Agents
Correspondence to: Dr. Peter C. Appelbaum Department of Pathology Hershey Medical Center P.O. Box 850 Hershey, PA 17033 Telephone… (More)
  • table 1
  • table 2
Is this relevant?
2005
2005
Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC range, 0… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2005
2005
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 microg/ml for 300 pneumococci… (More)
Is this relevant?
2004
2004
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were </=0.06 to 4.0 microg/ml for 258 isolates of Staphylococcus aureus… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?